Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular assessments, including laboratory tests and clinical evaluations. While approaches may overlap with metastatic settings, adjuvant treatment often emphasizes early detection of immune-related AEs, as patients are generally healthier.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

Now Viewing

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

• What is your approach to AE monitoring and management with adjuvant nivolumab? Does your approach differ at all in adjuvant vs metastatic setting?

Recent Videos